Sinegrip

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinegrip

Quick Facts

Property Description
Active ingredient Paracetamol (Acetaminophen) & Ascorbic Acid (Vitamin C)
Form Effervescent Tablet (Dissolves in water)
Pharmacological class Analgesic, Antipyretic, and Vitamin Combination
Common use Symptomatic relief of discomfort and malaise
Origin Synthetic/Derived Combination

What is Sinegrip and What is it Used For?

Sinegrip is a combination medication primarily classified as an Analgesic (pain reliever) and an Antipyretic (fever reducer). Its general purpose is to provide symptomatic relief from the general discomfort and feelings of malaise often associated with minor illnesses.

As a dual-action product, Sinegrip is designed to help address two of the most common signs of feeling unwell: elevated body temperature and physical aches. The active ingredient Paracetamol is widely used to temporarily reduce fever and relieve minor aches. The active ingredients work systemically throughout the body when taken by mouth to provide broad relief.


What Ingredients are in Sinegrip and What is its Form?

Sinegrip contains two main active ingredients: Paracetamol (Acetaminophen) and Ascorbic Acid (Vitamin C). It is a differentiated combination product typically available as an effervescent tablet intended for oral administration after being dissolved in water.

Paracetamol is a synthetic compound that provides the core analgesic and antipyretic properties, making Sinegrip a member of the Anilides class of drugs. The effervescent form is a key differentiator from standard tablets, as the formulation is often perceived to offer faster absorption. The addition of Vitamin C, a common nutrient that supports the body's natural functions, is for its role in supporting general immune function. Because it is dissolved completely before consumption, the effervescent form is generally considered to be easier to swallow than solid forms.

What side effects are possible with Sinegrip?

Possible Side Effects and Safety Information

The safety profile of Sinegrip is defined by the documented risks associated with its active components, particularly the decongestant Phenylpropanolamine (PPA) and the pain/fever reducer Acetaminophen.

Serious Adverse Reactions and Warnings

The regulatory focus for Sinegrip's components centers on two major, serious adverse reactions:

  • Hemorrhagic Stroke (Bleeding in the Brain): The Phenylpropanolamine component has been associated with a very low but increased risk of hemorrhagic stroke, which can be life-threatening. This risk was observed primarily in women, but men may also be at risk. The increased risk was noted within the first three days of starting use, prompting a public health warning and a request by the U.S. Food and Drug Administration (FDA) for the discontinuation of all drug products containing PPA.

  • Severe Skin Reactions: The Acetaminophen component carries a rare, but serious, risk of severe skin reactions, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP). These conditions are life-threatening and require immediate medical attention. Symptoms may include skin reddening, rash, and blisters. This necessitates a formal 'Allergy alert' warning on product labels.

Safety Restrictions and Context-of-Use Notes

Due to the association with hemorrhagic stroke, governmental regulatory authorities formally concluded that Phenylpropanolamine could not be considered safe for continued use given the seriousness of the potential event and the availability of alternative treatments. For the Acetaminophen component, patients must be warned that such severe skin reactions can occur at any time during treatment, even if the drug has been taken previously without issue.

Overdose and Emergency Response

Overdose and When to Seek Help

The primary toxicity risk in an overdose of Sinegrip is derived from the Paracetamol component, which is officially documented to cause severe, delayed organ damage. Excessive ingestion can lead to Acute Liver Failure and Hepatic Necrosis, outcomes that have been associated with the need for liver transplantation or Death.

Seeking Immediate Help

Regulatory authorities mandate that immediate medical attention must be sought or Poison Help contacted right away, even if the individual appears well or initial non-specific symptoms like nausea, vomiting, and sweating have subsided. The decision to seek help is required to be independent of apparent symptoms because the most damaging effects on the liver are delayed.

Clinical Management and Risk Factors

Official management protocols emphasize time-critical intervention. The specific antidote, N-acetylcysteine (NAC), is required and is highly effective when administered within the first eight hours after ingestion. Management involves hospital admission for monitoring, including laboratory testing of plasma acetaminophen concentration and Liver Function Tests to guide supportive treatment. Risk of severe outcome is increased in patients with a history of Alcohol Use or existing Liver Disease. The Ascorbic Acid component is officially associated with the potential for Kidney Stones and a risk of Hemolysis in individuals with G6PD deficiency.

Therapeutic Uses of Sinegrip

Sinegrip is commonly used to help with symptomatic relief by addressing symptoms related to physical discomfort associated with minor, self-limiting illnesses. It is relevant when supportive symptom management is appropriate, offering supportive therapeutic benefits during acute episodes. The primary active ingredient is utilized as an analgesic and antipyretic for treating pain and fever.

Relief of Fever and Systemic Discomfort

This domain is applicable within clinical settings that involve acute or disruptive symptom patterns, such as those seen in the common cold and flu. It helps address symptom clusters that create noticeable physiological strain, including elevated body temperature, headache, muscular aches, and generalized body pains. This therapeutic support assists with contributing to improved comfort during periods of heightened symptoms associated with feverish states.

Supportive Care During Acute Illnesses

It is commonly used across conditions marked by increased physiological stress, where the inclusion of Ascorbic Acid (Vitamin C) provides supportive relief. The formulation is relevant in contexts involving heightened systemic discomfort. This may assist with maintaining a sense of stability when symptoms are more noticeable, supporting the patient during difficult episodes by easing distress.

Quick Fact: Use in Acute Symptomatic Episodes
Primary Domain: Applied across domains where additional symptomatic support is needed for systemic imbalance and physical discomfort.
Benefit Focus: Provides support that helps ease the overall symptom burden.
Typical Use: Addressing symptom clusters of fever, headache, and body aches.

Regulatory References

  1. NIH StatPearls overview on Acetaminophen

Eligibility and Restrictions for Use

The official regulatory profile for Sinegrip (Paracetamol and Ascorbic Acid combination) establishes clear boundaries for who can and cannot use the medicine based on age, physiological state, and pre-existing medical conditions.

Contraindicated Use (Must Not Use)

Official labeling states the medicine is strictly prohibited for the following populations:

  • Individuals with severe hepatic impairment or severe active liver disease.
  • Patients with severe renal impairment.
  • Any person with a documented hypersensitivity to Paracetamol, Ascorbic Acid, or any product components.

Population Restrictions and Limitations

Use is not recommended for pregnant women and breastfeeding women, as safety data for the combination product is officially documented as insufficient. The medicine is generally contraindicated or not established for use in children under the minimum age specified by the regulatory authority (typically 12 or 16 years).

Use Requiring Caution

Conditional use is indicated for patients with non-severe hepatic impairment, chronic alcoholism, or conditions leading to glutathione deficiency. Additionally, caution is advised for patients on a sodium-restricted diet due to the effervescent formulation, and for those with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.

What should I know about interactions with other medicines?

This section outlines interaction information for Sinegrip (Paracetamol and Ascorbic Acid) based strictly on authoritative government regulatory documents.

Classification Official Regulatory Information
Contraindicated Combination Co-administration is formally prohibited with any other medicinal product containing acetaminophen to prevent exceeding established exposure limits and subsequent liver injury.
Pharmacodynamic Risk High-dose Paracetamol can potentiate the anticoagulant effect of oral anticoagulants (e.g., Warfarin), leading to a documented increase in International Normalized Ratio (INR).
Metabolic and Enzyme Risk Chronic, excessive alcohol consumption is officially noted to increase the risk of hepatotoxicity through the induction of hepatic microsomal enzymes. Co-use with Hepatic Enzyme Inducers (e.g., Barbiturates) may increase the risk of toxic effects.
Exposure Modification Ascorbic Acid causes urine acidification, resulting in officially described decreased plasma concentrations and altered clearance of certain pH-sensitive medicines, such as Amphetamine.
Acute Metabolic Risk Co-administration with Flucloxacillin is associated with an increased risk of High Anion Gap Metabolic Acidosis (HAGMA), particularly heightened in patients with severe renal impairment.
Product Form Constraint The effervescent formulation contains sodium, which must be considered in patients adhering to sodium-restricted diets. Use is also associated with a hemolysis risk in individuals with G6PD deficiency.

The regulatory profile defines two primary constraints: absolute prohibition to prevent overdose risk, and required monitoring of co-administered substances due to potential pharmacodynamic potentiation. This profile strictly details only documented regulatory restrictions and interactions.

Mechanism of Action

The core action of Paracetamol is the functional inhibition of the Cyclooxygenase ( COX) enzyme system predominantly within the Central Nervous System (CNS). This targeted effect reduces the synthesis of prostaglandin mediators, which are key mediators in the setting of the hypothalamic thermoregulatory set-point and in the sensitization of nociceptive pathways.

Beyond COX inhibition, the drug's mechanism involves modulation of descending neural pathways that inhibit nociceptive signals. This is achieved via an active metabolite that interacts with systems like the endocannabinoid and TRPV1 receptors. This dual-action pathway modulates both the generation and transmission of nociceptive signals, leading to diminished signaling within pain pathways.

Ascorbic Acid contributes a distinct mechanism by acting as a systemic, non-specific antioxidant. Its role is to scavenge Reactive Oxygen Species ( ROS) and free radicals that are often generated during systemic physiological stress. This action influences general cellular oxidative balance and provides functional complementarity to the CNS pathway modulation mechanisms.

Dosage and Administration Information

How to Use Sinegrip — Official Administration Guidelines

The administration of Sinegrip, a combination product containing Paracetamol (Acetaminophen) and Ascorbic Acid, is defined by established guidelines that govern its preparation and dosing schedule. The medicine is intended for oral use only, following a specific dissolution process.


Administration Scope

Rule Instruction/Entity
Route of administration Oral, administered as a solution after proper preparation.
Official dosing rules (Adults) A single dose ranges from 500 mg to 1000 mg of Paracetamol. The absolute maximum labeled dose of Paracetamol in any 24-hour period is 4000 mg.
Frequency and timing Doses should be repeated as required, maintaining a minimum interval of four hours between consecutive doses.
Timing in relation to meals Intake is typically permitted with or without food.
Preparation requirements The effervescent tablet must be placed in a full glass of water and allowed to dissolve completely before the solution is consumed immediately.
Course duration limits Continuous self-medication is generally limited to a maximum of 3 days for fever or 5 to 7 days for pain.

Population and Procedural Conditions

Official instructions detail dose adjustments for certain populations. For adults with moderate renal impairment, the dose interval must be extended to 6 hours, and for those with severe impairment, the interval is extended to 8 hours. Due to formulation components, the inclusion of sodium must be considered for patients on sodium-restricted diets, and aspartame requires attention for individuals with Phenylketonuria (PKU).


Resulting Procedural Structure

The required sequence for use involves first dissolving the tablet in water, then immediately consuming the complete solution, and lastly, adhering strictly to the four-hour minimum between doses.

Recent Clinical Evidence

Research Evidence / Overview of studies for Sinegrip


Evidence for Symptomatic Relief of Cold and Flu-Like Illnesses

Research exploring temporary relief of discomfort during acute illness, such as the common cold and flu-like syndromes, primarily comes from short-term Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These methods examined how the analgesic component (Paracetamol) affects symptoms. Researchers focused on outcomes related to physical discomfort, specifically measuring changes in patient-reported headache and muscular aches. They also monitored changes in elevated body temperature in adults and children.

Studies report how symptoms evolved in the observed populations. Research has explored outcomes related to systemic or functional imbalance and measured the temporary change in elevated body temperature. Findings were mixed when research examined other cold symptoms, such as a sore throat or cough. Evidence is limited regarding the component's impact on the overall duration of the illness.


Evidence on the Supportive Role of Ascorbic Acid (Vitamin C)

The role of the Ascorbic Acid component has been evaluated in large-scale Systematic Reviews and Meta-analyses. Research examined its use for outcomes related to total duration and severity of common cold symptoms. Studies monitored patient-reported outcomes in the general adult and pediatric population.

Findings describe patterns observed in studies related to a change in the total number of days a patient experiences cold symptoms, primarily in populations that maintained regular, continuous intake. Research indicates that for the general population, no noticeable effect was observed on preventing the common cold. Evidence is limited and inconsistent for the therapeutic use of Ascorbic Acid when started after symptoms have begun.


Long-Term Research and Study Follow-up Durations

Research examining acute changes typically focuses on short-term follow-up, often spanning only the immediate 48-72 hours of the acute illness. In contrast, studies observing the supportive component involved long-term research conducted over periods of several years. Long-term effects of the research on the combined ingredients not fully established by the currently available data.

Key Studies & References

  1. Acetaminophen. National Library of Medicine, MedlinePlus Drug Information.
  2. Acetaminophen. NIH StatPearls.

Frequently Asked Questions (FAQ)

Common questions about Sinegrip (FAQ)


Q: Is Sinegrip the same as other cold and flu medicines?

A: Official documents describe Sinegrip as a combination product. It contains Paracetamol (for pain and fever) and Ascorbic Acid (Vitamin C). This composition differentiates it from remedies that rely only on a single ingredient or those that contain other active compounds, such as decongestants or antihistamines.


Q: What are the most commonly reported side effects of Sinegrip?

A: Regulatory documents list common, less severe adverse reactions associated with the analgesic component (Paracetamol). These typically include effects such as nausea, vomiting, dizziness, or headache. Serious reactions, such as severe skin reactions, are possible but rarely reported.


Q: How long does it typically take for Sinegrip to start working?

A: Clinical data generally indicates that the analgesic component begins to provide relief within 15 to 30 minutes after taking the oral solution. The onset of action, or the time it takes to start working, is generally subject to individual physiological differences.


Q: How long does the effect of one dose of Sinegrip usually last?

A: Official dosing instructions require maintaining a minimum interval of four hours between consecutive doses. This dosing frequency is defined based on the established safety and efficacy profiles of the medicine's components.


Q: Can Sinegrip be used by older adults (e.g., over 65)?

A: Regulatory guidelines often reference the standard adult dosages for older patients. Caution is advised, and dose adjustments may be necessary if a person has pre-existing conditions like kidney or liver impairment, which can be more common in this population.


Q: Can Sinegrip be taken for a non-flu-related headache?

A: Official product information states that the medicine is indicated for the symptomatic treatment of mild to moderate pain of various origins. Pain relief is a primary purpose of the core analgesic component, in addition to relief from fever and cold affections.


Q: Does Sinegrip cause drowsiness or affect driving?

A: Regulatory documents for this specific Paracetamol and Ascorbic Acid formulation state that the active ingredients are not typically expected to cause drowsiness. Monitoring one's personal reaction to the medicine is advised in official warnings, though the medicine is not typically expected to impair the ability to drive or operate machinery.


Q: Are there any long-term side effects associated with Sinegrip?

A: The medicine is officially intended for short-term use only, limited to 3 to 7 days, depending on the symptom. Regulatory warnings describe that prolonged, regular high-dose use of the Paracetamol component is associated with risks, including the potential to enhance the effects of certain oral anticoagulants.


Q: Does Sinegrip interact with common dietary supplements?

A: The Ascorbic Acid component may increase the body's absorption of Iron from supplements. High doses of Ascorbic Acid may also affect the action of certain blood-thinning medicines. The importance of notifying a healthcare professional about all supplements being used is emphasized in official documents.


Q: Why does Sinegrip have different strengths available?

A: Official regulatory documents explain that different strengths are made available to allow for flexibility in dosing. This is done to meet the specific requirements of regulatory dosing guidelines based on a person's age or body weight.


Q: How is Sinegrip different from a standard pain reliever?

A: Sinegrip is officially classified as a combination product that contains both the pain reliever Paracetamol and Ascorbic Acid (Vitamin C). Additionally, the medicine is typically supplied as an effervescent tablet, which must be dissolved in water before consumption.


Q: Is it normal to feel a bit dizzy after taking Sinegrip?

A: Dizziness is listed in regulatory documents as an uncommon or rare adverse effect associated with the analgesic component. Official safety information notes that if a person experiences this or other unusual reactions, continued use should be assessed against the official warnings.


Q: What is the recommended duration of use for Sinegrip?

A: Official guidelines advise that self-medication should be limited to a maximum of 3 days for fever or 5 to 7 days for pain. Official guidelines indicate that use extending beyond these established limits requires professional assessment.


Q: Does taking Sinegrip prevent me from catching the flu?

A: Research examining the Ascorbic Acid component indicates that for the general population, no noticeable effect was observed on preventing the common cold. The medicine is intended for the temporary relief of symptoms during illness, not for prevention.


Q: Can Sinegrip be crushed or chewed instead of swallowed whole?

A: No, this medicine is an effervescent tablet that must be prepared according to the official instructions. It should be placed in a full glass of water and allowed to dissolve completely before the resulting solution is consumed immediately.


Q: Is Sinegrip available over the counter or is a prescription always required?

A: Products containing only Paracetamol and Ascorbic Acid at standard doses are typically classified by regulatory authorities as Over-The-Counter (OTC) or non-prescription medicines. This means they are often available for purchase without a doctor’s prescription.


Q: Why do some people experience insomnia after taking Sinegrip?

A: Official regulatory documents may list insomnia or sleep disorders as uncommon or rare side effects associated with the Paracetamol component. While this is not frequent, it is a documented possibility.


Q: Does Sinegrip cause stomach upset?

A: Commonly reported side effects of the analgesic component include nausea, vomiting, and other general gastrointestinal disturbances. These reactions are typically mild and transient.


Q: How does Sinegrip compare to cold remedies that contain only one active ingredient?

A: Official documentation states that this is a combination medicine that addresses symptoms using two active components: Paracetamol for pain and fever, and Ascorbic Acid for general supportive needs. Single-ingredient remedies only provide the function of one active compound.


Q: Can I use Sinegrip if I have asthma or breathing difficulties?

A: Official regulatory information does not list asthma as an absolute contraindication for Paracetamol. However, caution is advised for patients with aspirin-sensitive asthma due to a potential for cross-reactivity, and for those with severe infections that may lead to metabolic acidosis.


Q: Why are people often told to only take Sinegrip for a short period?

A: The restriction on duration (3-7 days) is officially in place to minimize two key risks. One is to avoid masking symptoms of a serious, underlying condition, and the other is to reduce the potential for serious adverse effects associated with long-term use of the active ingredients.


Q: Does Sinegrip contain caffeine or any other stimulant?

A: The active ingredients listed in the official composition are only Paracetamol and Ascorbic Acid. No stimulants, such as caffeine or pseudoephedrine, are listed as active components in this specific formulation.


Q: Can I take Sinegrip with other prescription medications not related to the flu?

A: The medicine is known to interact with specific medications, including certain oral anticoagulants and hepatic enzyme inducers. The official documentation emphasizes the importance of sharing information about all prescription medicines with a healthcare professional before use, due to the potential for known and unknown drug interactions.


Q: Does Sinegrip interfere with laboratory blood tests?

A: Official documentation indicates that the active components may affect certain laboratory tests. Paracetamol can interfere with the determination of uric acid and blood sugar levels, and high doses of Ascorbic Acid may also affect test results.


Q: Do official documents mention any potential long-term organ damage from Sinegrip?

A: Regulatory warnings emphasize the risk of severe liver damage from Paracetamol overdose or chronic use at high doses. Use of the medicine is prohibited in patients with severe hepatic impairment because of the established dose-dependent liver toxicity risk associated with Paracetamol.


Q: Is the onset of action faster if I take Sinegrip with food?

A: While the medicine can typically be taken with or without food, official pharmacokinetic data indicates that the rate of absorption of the analgesic component may be delayed when taken with a high-carbohydrate meal. This indicates a possible delay in the onset of symptomatic relief.


Q: Why do official sources list specific diseases where Sinegrip is contraindicated?

A: Contraindications are officially listed to prevent the risk of severe harm. For example, severe hepatic impairment is prohibited due to the established risk of Paracetamol's dose-dependent liver toxicity. Other prohibitions relate to specific known safety risks with the active components.


Q: What does the research say about Sinegrip's side effects in young adults?

A: Clinical trials and regulatory summaries of the analgesic component typically focused on outcomes for the general adult and pediatric populations. Specific side effect data for a narrow 'young adult' age group is generally not established or detailed separately in high-level regulatory summaries.


Q: Is Sinegrip intended for use in children?

A: The medicine is typically not established or contraindicated for use in children below a specific minimum age, which is often 12 or 16 years, depending on the regulatory authority. This is due to formulation component limits or lack of necessary safety data for that age group.


Q: Does Sinegrip interact with antidepressant medications?

A: Both active ingredients have documented potential interactions. Ascorbic Acid may interact with certain pH-sensitive medications, which includes some psychotropic drugs. Paracetamol can also interact with certain hepatic enzyme inducers. Regulatory authorities emphasize the need for professional assessment when combining this medicine with other treatments.

How should Sinegrip be stored and disposed of?

Storage Requirements

Sinegrip must be stored in the original container and protected from both light and moisture to prevent product degradation. The required temperature is below 30 C. If the product is supplied in a tube, the container must be kept tightly closed after each use.

Stability and Child Safety

To ensure product stability, the medicine should be used within one month of first opening the container. Additionally, the solution prepared from the effervescent tablet is stable for 8 hours after dissolving. All medicines must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Sinegrip should not be disposed of via wastewater or household trash. Patients must ask a pharmacist or utilize authorized local collection programs for proper environmental disposal, as required by regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sinegrip found in:

A-Z Index: